Search

Your search keyword '"Helmberger, T."' showing total 705 results
Start Over Author "Helmberger, T."
705 results on '"Helmberger, T."'

1. Transarterial Radioembolisation with Y90 Resin Microspheres and the Effect of Reimbursement Criteria in France: Final Results of the CIRT-FR Prospective Observational Study: M. Ronot el al.: Transarterial Radioembolisation with Y90 Resin …

Author

Ronot, M., Loffroy, R., Arnold, D., Greget, M., Sengel, C., Pinaquy, J. B., Pellerin, O., Maleux, G., Peynircioglu, B., Pelage, J. P., Schaefer, N., Sangro, B., de Jong, N., Zeka, B., Urdaniz, M., Helmberger, T., and Vilgrain, V.

Published
2025
Full Text
View/download PDF

2. Left atrial appendage volume is an independent predictor of atrial arrhythmia recurrence following cryoballoon pulmonary vein isolation in persistent atrial fibrillation

Author

Pongratz, J., primary, Riess, L., additional, Hartl, S., additional, Brueck, B., additional, Tesche, C., additional, Ebersberger, U., additional, Helmberger, T., additional, Crispin, A., additional, Wankerl, M., additional, Dorwarth, U., additional, Hoffmann, E., additional, and Straube, F., additional

Published
2023
Full Text
View/download PDF

9. Arterielle Verschlusskrankheit

Author

Treitl, M., Strube, H., Helmberger, T., and Reiser, M.

Abstract

Zusammenfassung: Leitlinien dienen zur Etablierung einheitlicher Behandlungsstandards und tragen zur Orientierung und Absicherung des behandelnden Arztes bei. Die periphere arterielle Verschlusskrankheit (pAVK) lässt sich in die Stadien Claudicatio intermittens, chronisch-kritische Ischämie und akute Ischämie unterteilen. Da diese Krankheitsbilder häufig und auch vital bedrohlich auftreten, sind aktuelle Leitlinien zur Diagnostik und stadiengerechten Therapie für den behandelnden Arzt auch aus forensischen Gründen von großer Bedeutung. Die vorliegende Übersicht stellt aktuelle Prinzipien der Diagnostik und Therapie sowie aktuelle Entwicklungen auf dem Gebiet der peripheren Gefäßintervention unter Berücksichtigung aktueller nationaler und internationaler Leitlinien, insbesondere des Transatlantic Intersociety Consensus (TASC) dar.

Published
2024
Full Text
View/download PDF

10. Solide pseudopapilläre Tumoren des Pankreas

Author

Herrmann, K.A., Helmberger, T., Bruns, C., Reiser, M.F., and Zech, C.J.

Abstract

Zusammenfassung: Solide pseudopapilläre Tumoren des Pankreas (SPTP) sind seltene Entitäten mit niedrigem Malignitätsgrad, die überwiegend bei jungen Frauen auftreten, typischerweise aus soliden, zystischen und zentral hämorrhagischen Komponenten bestehen und eine sehr gute Prognose haben. In der bildgebenden Diagnostik stellen sie sich relativ charakteristisch dar: rund bis ovalär, glatt begrenzt mit einer fibrotischen Pseudokapsel, die das meist gemischt solide und zystisch-hämorrhagische Tumorgewebe umgibt. Nach Kontrastmittelgabe zeigen SPTP eine protrahierte randständige Kontrastmittelaufnahme. Kalzifikationen können im Randbereich des Tumors vorkommen. Die MRT ist der CT bei der Diagnostik der hämorrhagischen Veränderungen überlegen. Das Bewusstsein und die Kenntnis der SPTP bei Radiologen und Chirurgen ist eine der wichtigsten Voraussetzungen für die korrekte Diagnose dieser seltenen Tumorentität mit exzellenter Prognose nach chirurgischer Therapie.

Published
2024
Full Text
View/download PDF

15. Allgemeine diagnostische Prinzipien

Author

Sendler, A., Dittler, H. J., Prantl, L., Weber, W. A., Avril, N., Brücher, B. L. D. M., Schwaiger, M., Helmberger, T., Reiser, M., Wolter, C., Neumeier, D., Schenck, U., Höfler, H., Werner, M., Feussner, H., Siewert, J. R., editor, Harder, F., editor, and Rothmund, M., editor

Published
2001
Full Text
View/download PDF

19. S3 Guideline: Diagnosis and Therapy of Biliary Carcinoma Short Version 2.00-June 2021, AWMF Register Number: 032-053OL

Author

Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Bloedt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougere, C., Freudenberger, P., Geier, A., Gkika, E., Goetz, M., Hammes, E., Helmberger, T., Hoffmann, R. T., Hofmann, W. P., Huppert, P., Kautz, A., Knoetgen, G., Koerber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H. P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, U., Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I, Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I, Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Woerns, M. A., Galle, P., Malek, N., Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Bloedt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougere, C., Freudenberger, P., Geier, A., Gkika, E., Goetz, M., Hammes, E., Helmberger, T., Hoffmann, R. T., Hofmann, W. P., Huppert, P., Kautz, A., Knoetgen, G., Koerber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H. P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, U., Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I, Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I, Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Woerns, M. A., Galle, P., and Malek, N.

Published
2022

20. S3-Guideline - Diagnosis and Therapy of Biliary Carcinoma

Author

Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Bloedt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougere, C., Freudenberger, P., Geier, A., Gkika, E., Goetz, M., Hammes, E., Helmberger, T., Hoffmann, R. T., Hofmann, W. P., Huppert, P., Kautz, A., Knoetgen, G., Koerber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H. P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, U., Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I, Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I, Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Woerns, M. A., Galle, P., Malek, N., Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Bloedt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougere, C., Freudenberger, P., Geier, A., Gkika, E., Goetz, M., Hammes, E., Helmberger, T., Hoffmann, R. T., Hofmann, W. P., Huppert, P., Kautz, A., Knoetgen, G., Koerber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H. P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, U., Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I, Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I, Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Woerns, M. A., Galle, P., and Malek, N.

Published
2022

21. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome

Author

Bitzer, M., additional, Voesch, S., additional, Albert, J., additional, Bartenstein, P., additional, Bechstein, W., additional, Blödt, S., additional, Brunner, T., additional, Dombrowski, F., additional, Evert, M., additional, Follmann, M., additional, La Fougère, C., additional, Freudenberger, P., additional, Geier, A., additional, Gkika, E., additional, Götz, M., additional, Hammes, E., additional, Helmberger, T., additional, Hoffmann, R. T., additional, Hofmann, W. P., additional, Huppert, P., additional, Kautz, A., additional, Knötgen, G., additional, Körber, J., additional, Krug, D., additional, Lammert, F., additional, Lang, H., additional, Langer, T., additional, Lenz, P., additional, Mahnken, A., additional, Meining, A., additional, Micke, O., additional, Nadalin, S., additional, Nguyen, H. P., additional, Ockenga, J., additional, Oldhafer, K., additional, Paprottka, P., additional, Paradies, K., additional, Pereira, P., additional, Persigehl, T., additional, Plauth, M., additional, Plentz, R., additional, Pohl, J., additional, Riemer, J., additional, Reimer, P., additional, Ringwald, J., additional, Ritterbusch, U., additional, Roeb, E., additional, Schellhaas, B., additional, Schirmacher, P., additional, Schmid, I., additional, Schuler, A., additional, von Schweinitz, D., additional, Seehofer, D., additional, Sinn, M., additional, Stein, A., additional, Stengel, A., additional, Steubesand, N., additional, Stoll, C., additional, Tannapfel, A., additional, Taubert, A., additional, Trojan, J., additional, van Thiel, I., additional, Tholen, R., additional, Vogel, A., additional, Vogl, T., additional, Vorwerk, H., additional, Wacker, F., additional, Waidmann, O., additional, Wedemeyer, H., additional, Wege, H., additional, Wildner, D., additional, Wittekind, C., additional, Wörns, M. A., additional, Galle, P., additional, and Malek, N., additional

Published
2022
Full Text
View/download PDF

22. S3-Leitlinie – Diagnostik und Therapie biliärer Karzinome

Author

Bitzer, M., Voesch, S., Albert, J., Bartenstein, P., Bechstein, W., Blödt, S., Brunner, T., Dombrowski, F., Evert, M., Follmann, M., La Fougère, C., Freudenberger, P., Geier, A., Gkika, E., Götz, M., Hammes, E., Helmberger, T., Hoffmann, R.T., Hofmann, W.P., Huppert, P., Kautz, A., Knötgen, G., Körber, J., Krug, D., Lammert, F., Lang, H., Langer, T., Lenz, P., Mahnken, A., Meining, A., Micke, O., Nadalin, S., Nguyen, H.P., Ockenga, J., Oldhafer, K., Paprottka, P., Paradies, K., Pereira, P., Persigehl, T., Plauth, M., Plentz, R., Pohl, J., Riemer, J., Reimer, P., Ringwald, J., Ritterbusch, Ulrike, Roeb, E., Schellhaas, B., Schirmacher, P., Schmid, I., Schuler, A., von Schweinitz, D., Seehofer, D., Sinn, M., Stein, A., Stengel, A., Steubesand, N., Stoll, C., Tannapfel, A., Taubert, A., Trojan, J., van Thiel, I., Tholen, R., Vogel, A., Vogl, T., Vorwerk, H., Wacker, F., Waidmann, O., Wedemeyer, H., Wege, H., Wildner, D., Wittekind, C., Wörns, M.A., Galle, P., and Malek, N.

Subjects
Medizin
Published
2022

23. Clinical Application of Trans-Arterial Radioembolization in Hepatic Malignancies in Europe: First Results from the Prospective Multicentre Observational Study CIRSE Registry for SIR-Spheres Therapy (CIRT)

Author

Helmberger T., Golfieri R., Pech M., Pfammatter T., Arnold D., Cianni R., Maleux G., Munneke G., Pellerin O., Peynircioglu B., Sangro B., Schaefer N., de Jong N., Bilbao J. I., Pelage J. -P., Manas D. M., Kolligs F. T., Ezziddin S., Peters R., Albrecht T., D'Archambeau O., Balli T., Bilgic S., Bloom A., Cioni R., Fischbach R., Flamen P., Gerard L., Grozinger G., Katoh M., Koehler M., Kroger J. R., Kuhl C., Orsi F., Ozgun M., Reimer P., Ronot M., Schmid A., Vit A., Helmberger T., Golfieri R., Pech M., Pfammatter T., Arnold D., Cianni R., Maleux G., Munneke G., Pellerin O., Peynircioglu B., Sangro B., Schaefer N., de Jong N., Bilbao J.I., Pelage J.-P., Manas D.M., Kolligs F.T., Ezziddin S., Peters R., Albrecht T., D'Archambeau O., Balli T., Bilgic S., Bloom A., Cioni R., Fischbach R., Flamen P., Gerard L., Grozinger G., Katoh M., Koehler M., Kroger J.R., Kuhl C., Orsi F., Ozgun M., Reimer P., Ronot M., Schmid A., Vit A., University of Zurich, On behalf of the CIRT Steering Committee, On behalf of the CIRT Principal Investigators, Pelage, J.P., Manas, D.M., Kolligs, F.T., Ezziddin, S., Peters, R., Albrecht, T., D'Archambeau, O., Balli, T., Bilgic, S., Bloom, A., Cioni, R., Fischbach, R., Flamen, P., Gerard, L., Grözinger, G., Katoh, M., Koehler, M., Kröger, J.R., Kuhl, C., Orsi, F., Ozgun, M., Reimer, P., Ronot, M., Schmid, A., and Vit, A.

Subjects
Male, Registrie, SIR-Spheres, Yttrium-90, Cardiac & Cardiovascular Systems, Tare weight, Colorectal cancer, Hepatocellular carcinoma, medicine.medical_treatment, Metastasi, Radioisotope brachytherapy, COLORECTAL-CANCER, Metastasis, 030218 nuclear medicine & medical imaging, 0302 clinical medicine, Observational study, Medicine, Yttrium Radioisotopes, Prospective Studies, Registries, SALVAGE THERAPY, Y-90 RADIOEMBOLIZATION, 10042 Clinic for Diagnostic and Interventional Radiology, Incidence, Mortality rate, Radiology, Nuclear Medicine & Medical Imaging, Liver Neoplasms, CANCER LIVER METASTASES, Middle Aged, Embolization, Therapeutic, Microspheres, Europe, Trans-arterial radioembolization, Liver, SAFETY, 030220 oncology & carcinogenesis, Female, Cardiology and Cardiovascular Medicine, Life Sciences & Biomedicine, medicine.medical_specialty, Carcinoma, Hepatocellular, 610 Medicine & health, Context (language use), Therapeutic embolization, 03 medical and health sciences, Breast cancer, GLASS MICROSPHERES, ADVANCED HEPATOCELLULAR-CARCINOMA, Pancreatic cancer, Internal medicine, INTRAHEPATIC CHOLANGIOCARCINOMA, Humans, Radiology, Nuclear Medicine and imaging, Clinical Investigation, Retrospective Studies, Science & Technology, INTERNAL RADIATION-THERAPY, business.industry, EFFICACY, medicine.disease, Radiography, Cardiovascular System & Cardiology, business
Abstract

Purpose To address the lack of prospective data on the real-life clinical application of trans-arterial radioembolization (TARE) in Europe, the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) initiated the prospective observational study CIRSE Registry for SIR-Spheres® Therapy (CIRT). Materials and Methods Patients were enrolled from 1 January 2015 till 31 December 2017. Eligible patients were adult patients treated with TARE with Y90 resin microspheres for primary or metastatic liver tumours. Patients were followed up for 24 months after treatment, whereas data on the clinical context of TARE, overall survival (OS) and safety were collected. Results Totally, 1027 patients were analysed. 68.2% of the intention of treatment was palliative. Up to half of the patients received systemic therapy and/or locoregional treatments prior to TARE (53.1%; 38.3%). Median overall survival (OS) was reported per cohort and was 16.5 months (95% confidence interval (CI) 14.2–19.3) for hepatocellular carcinoma, 14.6 months (95% CI 10.9–17.9) for intrahepatic cholangiocarcinoma. For liver metastases, median OS for colorectal cancer was 9.8 months (95% CI 8.3–12.9), 5.6 months for pancreatic cancer (95% CI 4.1–6.6), 10.6 months (95% CI 7.3–14.4) for breast cancer, 14.6 months (95% CI 7.3–21.4) for melanoma and 33.1 months (95% CI 22.1–nr) for neuroendocrine tumours. Statistically significant prognostic factors in terms of OS include the presence of ascites, cirrhosis, extra-hepatic disease, patient performance status (Eastern Cooperative Oncology Group), number of chemotherapy lines prior to TARE and tumour burden. Thirty-day mortality rate was 1.0%. 2.5% experienced adverse events grade 3 or 4 within 30 days after TARE. Conclusion In the real-life clinical setting, TARE is largely considered to be a part of a palliative treatment strategy across indications and provides an excellent safety profile. Level of evidence Level 3. Trial registration ClinicalTrials.gov NCT02305459.

Published
2021

41. The CIREL Cohort: A Prospective Controlled Registry Studying the Real-Life Use of Irinotecan-Loaded Chemoembolisation in Colorectal Cancer Liver Metastases: Interim Analysis

Author

Pereira, P.L. Iezzi, R. Manfredi, R. Carchesio, F. Bánsághi, Z. Brountzos, E. Spiliopoulos, S. Echevarria-Uraga, J.J. Gonçalves, B. Inchingolo, R. Nardella, M. Pellerin, O. Sousa, M. Arnold, D. de Baère, T. Gomez, F. Helmberger, T. Maleux, G. Prenen, H. Sangro, B. Zeka, B. Kaufmann, N. Taieb, J.

Abstract

Purpose: Transarterial chemoembolisation (TACE) using irinotecan-eluting beads is an additional treatment option for colorectal cancer liver metastases (CRLM) patients that are not eligible for curative treatment approaches. This interim analysis focuses on feasibility of the planned statistical analysis regarding data distribution and completeness, treatment intention, safety and health-related quality of life (HRQOL) of the first 50 patients prospectively enrolled in the CIrse REgistry for LifePearl™ microspheres (CIREL), an observational multicentre study conducted across Europe. Methods: In total, 50 patients ≥ 18 years diagnosed with CRLM and decided to be treated with irinotecan-eluting LifePearl™ microspheres TACE (LP-irinotecan TACE) by a multidisciplinary tumour board. There were no further inclusion or exclusion criteria. The primary endpoint is the categorisation of treatment intention, and secondary endpoints presented in this interim analysis are safety, treatment considerations and HRQOL. Results: LP-irinotecan TACE was conducted in 42% of patients as salvage therapy, 20% as an intensification treatment, 16% as a first-line treatment, 14% a consolidation treatment and 8% combination treatment with ablation with curative intent. Grade 3 and 4 adverse events were reported by 4% of patients during procedure and by 10% within 30 days. While 38% reported a worse, 62% reported a stable or better global health score, and 54% of patients with worse global health score were treated as salvage therapy patients. Conclusion: This interim analysis confirms in a prospective analysis the feasibility of the study, with an acceptable toxicity profile. More patients reported a stable or improved HRQOL than deterioration. Deterioration of HRQOL was seen especially in salvage therapy patients. Trial Registration: NCT03086096. © 2020, The Author(s).

Published
2021

44. P-130 Real-world outcomes of patients with colorectal liver metastases treated with transarterial radioembolization: Results from CIRT, a large European, prospective multi-centre, observational study

Author

Schaefer, N., primary, Sangro, B., additional, Kolligs, F., additional, Maleux, G., additional, Pech, M., additional, Soydal, C., additional, Pfammatter, T., additional, Groezinger, G., additional, de Jong, N., additional, and Helmberger, T., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results